The Company Once Again Named Among the “Top 100 Enterprises in Pharmaceutical Internationalization”


发布时间:2019-07-15

【概要描述】 From June 18 to 20, the 19th China International Pharmaceutical Ingredients Exhibition (CPhI China) was grandly held at the Shanghai New International Expo Center. On the eve of the exhibition, the winners of the 2019 Top 100 Globalized Pharmaceutical Companies ranking were announced, with Shijiazhuang Sihua Pharmaceutical Co., Ltd. once again making the list and being honored as a “Top 20 Leader in Formulation Globalization.” This underscores the strong international market recognition of Sihua’s products and reaffirms the company’s global strategy as endorsed by a leading authority.
 
From June 18 to 20, the 19th CPhI China—China International Pharmaceutical Ingredients Exhibition—grandly opened at the Shanghai New International Expo Center. On the eve of the show, the winners of the 2019 Top 100 Global Pharmaceutical Companies ranking were announced, with Shijiazhuang Sihua Pharmaceutical Co., Ltd. once again making the list and being honored as a “Top 20 Leader in Formulation Internationalization.” This underscores the strong international market recognition of Sihua’s products and reaffirms the company’s internationalization strategy as endorsed by a leading authority.
The “Top 100 Enterprises in Pharmaceutical Internationalization” list was unveiled at the “4th Selection of Top 100 Enterprises in Pharmaceutical Internationalization,” hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products. According to reports, this selection is the most authoritative and influential event in the field of pharmaceutical internationalization. The initiative aims to promote Chinese pharmaceutical companies that serve as benchmarks for the country’s internationalization and “going global” strategy in the global market, encourage innovation in international operations, enhance the international recognition and influence of leading Chinese firms in pharmaceutical internationalization, and establish industry standards for China’s pharmaceutical internationalization strategy.
In recent years, as the Foreign Trade Department has continuously explored international markets, the company’s capability for international operations has significantly improved. Last year, the company developed 37 new international customers, completed five international quality audits and certifications in countries such as the Netherlands and Pakistan, secured product registrations in a total of 83 countries covering 131 product specifications and varieties, and achieved year-on-year growth in export volumes, making this a new highlight of the company’s innovative business practices.

Keywords: